LACTOLOGY FOUNDATION

Methantheline (ATC A03AB07) is a synthetic quaternary ammonium antimuscarinic used as an antispasmodic for functional gastrointestinal and urinary tract disorders, but like other anticholinergics it carries dose‑dependent systemic toxicity and is generally not preferred during breastfeeding because of potential anticholinergic effects in the infant and possible reduction of milk production. Its quaternary structure limits central nervous system penetration compared with tertiary amines, yet significant peripheral anticholinergic adverse effects and serious toxicity can still occur in overdose or in vulnerable patients, especially infants and young children.medpedia.framar+6

Pharmacological profile

Methantheline is classified under ATC code A03AB07 within the group of synthetic anticholinergics, quaternary ammonium compounds, indicated for functional gastrointestinal disorders. It is a synthetic antispasmodic and antimuscarinic agent that competitively blocks acetylcholine at muscarinic receptors in smooth muscle and secretory tissues, particularly in the gastrointestinal tract and bladder.wikipedia+8

Clinically, methantheline bromide is used to reduce gastrointestinal motility and secretion in conditions such as peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorospasm, and neurogenic bladder instability. Its quaternary ammonium nature confers poor lipid solubility and limited blood–brain barrier penetration, which decreases but does not eliminate central anticholinergic effects compared with tertiary agents.drugbank+5

Mechanism of action

Methantheline exerts its principal effect by competitive antagonism of acetylcholine at muscarinic receptors, leading to inhibition of parasympathetic activity in target organs. In the gastrointestinal tract, this produces decreased smooth muscle tone, reduced peristalsis, and diminished gastric and pancreatic secretions, thereby relieving spasms and hypermotility.drugs.ncats+4

In the urinary tract, blockade of detrusor muscarinic receptors reduces bladder contractions and can help manage reflex neurogenic bladder and urinary urgency in selected patients. Systemically, antimuscarinic effects may also involve salivary glands, eyes, heart, and sweat glands, producing a characteristic anticholinergic profile.wikipedia+5

Indications and clinical use

Methantheline is prescribed as an adjunctive antispasmodic therapy in functional gastrointestinal disorders characterized by cramping, pain, and motility disturbances. Indicated uses include peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorospasm, and selected cases of neurogenic bladder instability or reflex neurogenic bladder in children.drugbank+3

It is typically administered orally, with dosage and titration individualized based on symptom severity, patient age, and comorbidities, and it is dispensed as a prescription‑only medicine. Because of its anticholinergic burden and the availability of alternative therapies with better safety profiles, methantheline is less frequently used in contemporary practice and may be reserved for specific clinical scenarios.clevelandclinic+4

Contraindications and precautions

Methantheline should not be used in patients with known hypersensitivity to the drug or its excipients, as reflected in product information. As with other anticholinergics, important contraindications include conditions where reduced cholinergic tone can worsen disease, such as untreated narrow‑angle glaucoma, obstructive uropathy (for example, prostatic hypertrophy with urinary retention risk), intestinal obstruction, paralytic ileus, and severe ulcerative colitis with risk of toxic megacolon.rch+4

Caution is required in elderly patients, those with cardiovascular disease (risk of tachycardia), autonomic neuropathies, hepatic or renal impairment, and patients concurrently receiving other anticholinergic or anticholinergic‑burden medications (antihistamines, tricyclic antidepressants, antipsychotics, antiparkinsonian agents). Pre‑existing gastro‑oesophageal reflux, xerostomia, or chronic constipation can be exacerbated by methantheline due to its inhibitory effects on secretions and motility.wikem+3

Adverse effects

The adverse effect profile of methantheline parallels that of other peripheral antimuscarinic agents. Common dose‑dependent reactions include dry mouth, decreased sweating, dry eyes and blurred vision due to mydriasis, constipation, urinary retention, and tachycardia.drugbank+5

Patients may experience dizziness, impaired accommodation, photophobia, and, less commonly, confusion or agitation, especially if higher doses are used or if central penetration occurs in susceptible individuals. Reduced sweating and vasodilation can predispose to heat intolerance and hyperthermia, particularly in hot environments or during physical exertion.wikipedia+2

Toxicity and overdose

Methantheline overdose produces an anticholinergic toxidrome consistent with other antimuscarinic agents. Clinical manifestations often follow the classic pattern: tachycardia, dry flushed skin, hyperthermia, mydriasis with blurred vision, decreased bowel sounds, urinary retention, agitation, delirium, and, in severe cases, seizures and coma.rch+2

Management of methantheline toxicity is primarily supportive, focusing on airway, breathing, and circulation, control of agitation and seizures (for example with benzodiazepines), correction of hyperthermia with external cooling, and treatment of complications such as urinary retention. In selected severe cases of anticholinergic delirium without contraindications, physostigmine may be considered in consultation with a toxicologist, although careful monitoring for bradyarrhythmias and cholinergic excess is essential.wikem+1

Because methantheline is a quaternary compound, central symptoms might be somewhat attenuated compared with tertiary anticholinergics, yet significant systemic toxicity still occurs and children are particularly vulnerable to even moderate overdoses.drugs.ncats+3

Use in pregnancy

Specific controlled studies of methantheline use in pregnancy are limited, and dedicated teratogenicity data are sparse. General principles for anticholinergic use in pregnancy therefore apply: avoid use unless the expected benefit to the mother outweighs potential risks to the fetus, use the lowest effective dose for the shortest duration, and prefer agents with more robust safety data when available.msdmanuals+4

Given the class mechanism, potential concerns include maternal tachycardia, reduced gastrointestinal motility, and possible effects on uterine or bladder function, though clear human data are lacking. Decisions about methantheline in pregnancy should be individualized, ideally in consultation with obstetric and gastroenterology specialists.hse+3

Use during lactation

There are no robust lactation‑specific pharmacokinetic or clinical studies for methantheline, and it is not commonly listed among standard reference examples of drugs evaluated in breastfeeding. General breastfeeding pharmacology indicates that many medications appear in breast milk in small quantities, and most are compatible with breastfeeding when used at therapeutic doses, but anticholinergic drugs raise particular concern because they may reduce milk production and cause anticholinergic effects in the infant.franciscanhealth+6

As a quaternary ammonium compound with low lipid solubility, methantheline may have reduced transfer into breast milk compared with more lipophilic tertiary amines, but this theoretical pharmacokinetic advantage is not sufficient to guarantee safety in the absence of clinical data. Anticholinergic exposure through breast milk could, in principle, lead to infant symptoms such as dry mouth, reduced gastrointestinal motility (constipation or ileus), urinary retention, tachycardia, and sedation or agitation, particularly in neonates and young infants.nhs+6

Furthermore, anticholinergics can interfere with prolactin‑mediated lactogenesis and oxytocin‑mediated milk ejection, potentially reducing milk supply, especially when initiated early postpartum or used at higher doses. Because safer alternatives for functional gastrointestinal symptoms during breastfeeding exist (for example, non‑anticholinergic antispasmodics or symptomatic treatments supported by breastfeeding guidelines), methantheline would generally not be a first‑line choice for lactating women and should be reserved, if at all, for situations where benefits clearly outweigh risks and close monitoring is feasible.msdmanuals+4

When methantheline use in a breastfeeding mother is considered unavoidable, practical risk‑minimization measures include using the lowest effective dose, limiting duration, taking doses immediately after breastfeeding or with the longest interval before the next feed, and careful observation of the infant for signs of anticholinergic effects or feeding difficulties. If concerning symptoms arise in the infant or milk production appears compromised, reassessment of therapy, dose reduction, substitution with a breastfeeding‑compatible alternative, or temporary interruption of breastfeeding may be indicated.franciscanhealth+3

Pediatric and geriatric considerations

Methantheline has been used in children for reflex neurogenic bladder, but pediatric patients are highly sensitive to anticholinergic effects, and dosing must be cautious with close monitoring. Anticholinergic toxicity is particularly dangerous in young children, in whom even relatively modest overdoses can produce severe hyperthermia, delirium, seizures, and cardiovascular instability.drugbank+3

In older adults, anticholinergic burden is associated with increased risks of confusion, cognitive impairment, falls, urinary retention, constipation, and exacerbation of glaucoma, making methantheline generally less desirable in geriatric practice when safer alternatives exist. Polypharmacy, especially with other anticholinergic medications, amplifies these risks and warrants regular review of therapy and deprescribing where appropriate.clevelandclinic+2

Drug interactions

Methantheline’s antimuscarinic action can be additive with other anticholinergic agents, increasing the likelihood of classic anticholinergic adverse effects and toxicity. Concomitant use with drugs such as first‑generation antihistamines, tricyclic antidepressants, antipsychotics with anticholinergic properties, antiparkinsonian anticholinergics, and certain antispasmodics can substantially elevate anticholinergic load.wikipedia+3

By decreasing gastrointestinal motility and secretions, methantheline may affect the absorption of other orally administered drugs, particularly those with narrow therapeutic indices or modified‑release formulations. Anticholinergic‑induced tachycardia may interact unfavorably with other chronotropic agents or in patients on medications affecting cardiac conduction, emphasizing the need for comprehensive medication review before initiating methantheline.rch+2

Practical toxicology–lactology assessment

From a toxicology standpoint, methantheline belongs to a pharmacological class with a well‑characterized anticholinergic toxidrome, and clinicians should maintain a low threshold for recognizing and treating anticholinergic toxicity in cases of overdose or polypharmacy. The quaternary structure may limit central effects but does not prevent severe peripheral toxicity, especially in extremes of age, patients with comorbidities, or in the presence of other anticholinergic drugs.drugs.ncats+4

From a lactology perspective, the absence of specific breastfeeding data, coupled with the theoretical risk of reduced milk production and infant anticholinergic exposure, supports a cautious approach that prioritizes non‑anticholinergic alternatives for functional gastrointestinal symptoms in lactating women whenever possible. If methantheline use is deemed necessary, individualized risk–benefit analysis, transparent counseling, and active monitoring of both mother and infant are essential components of safe practice.hse+4